Overexpression of Hepatic Lipase in Transgenic Mice Decreases Apolipoprotein B-containing and High Density Lipoproteins

To determine the mechanisms by which human hepatic lipase (HL) contributes to the metabolism of apolipoprotein (apo) B-containing lipoproteins and high density lipoproteins (HDL)in vivo, we developed and characterized HL transgenic mice. HL was localized by immunohistochemistry to the liver and to t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of biological chemistry 1998-01, Vol.273 (4), p.1896-1903
Hauptverfasser: Dichek, Helén L., Brecht, Walter, Fan, Jianglin, Ji, Zhong-Sheng, McCormick, Sally P.A., Akeefe, Hassibullah, Conzo, LoriAnna, Sanan, David A., Weisgraber, Karl H., Young, Stephen G., Taylor, John M., Mahley, Robert W.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To determine the mechanisms by which human hepatic lipase (HL) contributes to the metabolism of apolipoprotein (apo) B-containing lipoproteins and high density lipoproteins (HDL)in vivo, we developed and characterized HL transgenic mice. HL was localized by immunohistochemistry to the liver and to the adrenal cortex. In hemizygous (hHLTg+/0) and homozygous (hHLTg+/+) mice, postheparin plasma HL activity increased by 25- and 50-fold and plasma cholesterol levels decreased by 80% and 85%, respectively. In mice fed a high fat, high cholesterol diet to increase endogenous apoB-containing lipoproteins, plasma cholesterol decreased 33% (hHLTg+/0) and 75% (hHLTg+/+). Both apoB-containing remnant lipoproteins and HDL were reduced. To extend this observation, the HL transgene was expressed in human apoB transgenic (huBTg) and apoE-deficient (apoE−/−) mice, both of which have high plasma levels of apoB-containing lipoproteins. (Note that thehuBTg mice that were used in these studies were all hemizygous for the human apoB gene.) In both thehuBTg,hHLTg+/0 mice and theapoE−/−,hHLTg+/0mice, plasma cholesterol decreased by 50%. This decrease was reflected in both the apoB-containing and the HDL fractions. To determine if HL catalytic activity is required for these decreases, we expressed catalytically inactive HL (HL-CAT) in apoE−/−mice. The postheparin plasma HL activities were similar in theapoE−/− and theapoE−/−,HL-CAT+/0mice, reflecting the activity of the endogenous mouse HL and confirming that the HL-CAT was catalytically inactive. However, the postheparin plasma HL activity was 20-fold higher in theapoE−/−,hHLTg+/0mice, indicating expression of the active human HL. Immunoblotting demonstrated high levels of human HL in postheparin plasma of bothapoE−/−,hHLTg+/0and apoE−/−,HL-CAT+/0mice. Plasma cholesterol and apoB-containing lipoprotein levels were ∼60% lower inapoE−/−,HL-CAT+/0mice than in apoE−/− mice. However, the HDL were only minimally reduced. Thus, the catalytic activity of HL is critical for its effects on HDL but not for its effects on apoB-containing lipoproteins. These results provide evidence that HL can act as a ligand to remove apoB-containing lipoproteins from plasma.
ISSN:0021-9258
1083-351X
DOI:10.1074/jbc.273.4.1896